Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Lorin Johnson
AddedMar 31, 2024
UpdatedMay 31, 2026
Lorin Johnson

Lorin Johnson

Board Member, Glycyx

CrunchbaseLinkedIn

Lorin Johnson's Career

Glycyx
Glycyx

San Francisco, CA, US

Board Member· Board
Salix Pharmaceuticals
Salix Pharmaceuticals

Raleigh, NC, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Lorin Johnson's Career

Glycyx
Glycyx
Series A$3.6M72020San Francisco, CA, US
Board Member· Board

Leadership at Glycyx

Justin ChicklesJustin ChicklesFounder

Similar to Glycyx

GlycologixGlycologixBeverly, MA, USBiomaterials, Therapiesest. 2016GlycologixBeverly, MA, US · est. 2016

Glycologix: A biotech firm specializing in R&D for soft tissue protection and repair.

Pre-Seed · $2.9M6
GliknikGliknikBaltimore, MD, USBiopharmaceuticals, Cancer Therapiesest. 2007GliknikBaltimore, MD, US · est. 2007

US-based Gliknik, Inc. develops therapies for cancer and immune disorders, producing drugs that enhance immune responses and kill tumor cells.

Series C · $70.1M75
CybrexaCybrexaNew Haven, CT, USOncology, Therapeuticsest. 2017CybrexaNew Haven, CT, US · est. 2017

Cybrexa Therapeutics: A clinical-stage biotech firm, innovating in oncology with DNA repair inhibitors.

Series B · $44.4M38
GlycoMimeticsGlycoMimeticsRockville, MD, USDrugs, Pharmaceuticalsest. 2003GlycoMimeticsRockville, MD, US · est. 2003

US-based GlycoMimetics, Inc. researches, develops, and commercializes specialized drugs for blood cancers and inflammation.

Public · $373.4M39
Salix Pharmaceuticals
Salix Pharmaceuticals
Public$750M7501989Raleigh, NC, US
Founder

Leadership at Salix Pharmaceuticals

William P KeaneWilliam P KeaneBoard Member
Carolyn LoganCarolyn LoganBoard Member
John F ChappellJohn F ChappellBoard Member

People Similar to Lorin Johnson

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJohn MagnaniJohn MagnaniBoard Member · GlycoMimeticsShoba MuraliShoba MuraliBoard Member · UcanDaniel M. JuniusDaniel M. JuniusBoard Member · GlycoMimeticsJohn LorenzJohn LorenzBoard Member · GlyEcoRichard C. Cilento, Jr.Richard C. Cilento, Jr.Board Member · Glycos Biotechnologies